The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > ACADEMIA
ACADEMIA
- KOL Highlights Need for Further RSV Epidemiological Research in Japan
February 15, 2024
- Drug Loss Is Intensifying for Rare Cancers amid Rise of Biotech Developers: JSMO Director
February 5, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- National Geriatrics Center to Kick Off Leqembi Treatment on Feb. 13
January 25, 2024
- NCC Launches Investigator-Led Studies on 5 Unapproved, Off-Label Drugs for Pediatric, AYA Cancers
January 22, 2024
- Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
January 22, 2024
- Medical Interns Improperly Prescribe, Use GLP-1 Agent for Off-Label Purpose
December 18, 2023
- Japan Obesity Society Urges Attention to Suicidal Thoughts in Patients Who Use Wegovy
November 29, 2023
- Scientific Societies Urge Greater Caution for COVID Drug Use in Women of Childbearing Age
November 15, 2023
- Chemotherapy Society Urges Govt to Create Body to Spur Drug Discovery
October 31, 2023
- G1 Product Info Could Disappear after Withdrawal, PMDA Website Should Retain Posting: Pharmacist
October 11, 2023
- Flu Drug Spending Hits 48 Billion Yen in FY2017, NCGM Flags Cost-Effectiveness
October 10, 2023
- NCC Announces “No Placebo Initiative” for Cancer Trials
October 10, 2023
- Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
September 25, 2023
- Japan Society to Select Facilities to Use Luxturna; 10 Sites for Genetic Testing, 2 or 3 for Treatment
August 25, 2023
- Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
- NIID Researcher Contracts Typhoid Fever
August 21, 2023
- Long COVID Depression Persists among Elderly: NIBIOHN Study
July 26, 2023
- Thai Patients to Join NCC Clinical Studies in “World’s First” Cross-Border DCT Deal
June 29, 2023
- Japan’s NCC, Thailand Agree to Run Virtual Clinical Trials
June 15, 2023
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…